Xi Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xi Lin has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Jingyao Ma
Hematology Center National Key Discipline of Pediatrics (Capital Medical University) Beijing China
2 shared publications - Runhui Wu
Hematology Oncology Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China
2 shared publications - Shuyue Dong
Hematology Center National Key Discipline of Pediatrics (Capital Medical University) Beijing China
2 shared publications Xiaoling Cheng
Department of Pharmacy, Beijing Children's Hospital Capital Medical University Beijing China
2 shared publications- Yu Hu
Hematology Center National Key Discipline of Pediatrics (Capital Medical University) Beijing China
2 shared publications Zhenping Chen
Key Laboratory of Major Diseases in Children, Ministry of Education Beijing China
2 shared publications
Latest Publications
- 22 November 2025
- Published by Wiley in American Journal of Hematology
- Vol. 101 (2) , 384-387
Daratumumab in Pediatric Chronic Refractory Primary Immune Thrombocytopenia ( ITP ): Rapid Platelet Recovery, Sustained Response, and Immune Reconstitution Dynamics
- 22 November 2025
- Published by Wiley in American Journal of Hematology
- Vol. 101 (2) , 384-387
Daratumumab in Pediatric Chronic Refractory Primary Immune Thrombocytopenia ( ITP ): Rapid Platelet Recovery, Sustained Response, and Immune Reconstitution Dynamics
- 15 July 2025
- Published by Wiley in British Journal of Haematology
- Vol. 207 (2) , 463-474
Machine learning to forecast rituximab responses for paediatric immune thrombocytopenia: Forging a path towards personalized medical care
Summary: Primary immune thrombocytopenia (ITP) is an autoimmune disorder characterized by decreased platelet counts and increased bleeding risk. Although paediatric ITP often resolves spontaneously, some children do not respond to first‐line treatments, thus requiring rituximab as a second‐line therapy to reduce bleeding risks and corticosteroid exposure. Currently, there is no reliable method to predict the efficacy of rituximab. Our study aimed to develop a machine learning (ML) model to predict the initial response to rituximab in these patients. We analysed data from 156 paediatric ITP patients treated at Beijing Children's Hospital between 2020 and 2023 and identified 25 key predictive features. Among the four evaluated ML models, the multilayer perceptron model exhibited the highest predictive accuracy. SHapley Additive exPlanations analysis revealed that antinuclear antibody titre, thyroglobulin antibody, corticosteroid response and bleeding severity were significant positive predictors, while thyroid peroxidase antibody, CD3+ CD4+ IL‐17+ T cells and the duration of disease before rituximab treatment were negatively associated with treatment responses. This ML model could be used to predict rituximab responses in paediatric ITP, which is expected to optimize treatment strategies and improve patient outcomes.
- 15 July 2025
- Published by Wiley in British Journal of Haematology
- Vol. 207 (2) , 463-474
Machine learning to forecast rituximab responses for paediatric immune thrombocytopenia: Forging a path towards personalized medical care
Summary: Primary immune thrombocytopenia (ITP) is an autoimmune disorder characterized by decreased platelet counts and increased bleeding risk. Although paediatric ITP often resolves spontaneously, some children do not respond to first‐line treatments, thus requiring rituximab as a second‐line therapy to reduce bleeding risks and corticosteroid exposure. Currently, there is no reliable method to predict the efficacy of rituximab. Our study aimed to develop a machine learning (ML) model to predict the initial response to rituximab in these patients. We analysed data from 156 paediatric ITP patients treated at Beijing Children's Hospital between 2020 and 2023 and identified 25 key predictive features. Among the four evaluated ML models, the multilayer perceptron model exhibited the highest predictive accuracy. SHapley Additive exPlanations analysis revealed that antinuclear antibody titre, thyroglobulin antibody, corticosteroid response and bleeding severity were significant positive predictors, while thyroid peroxidase antibody, CD3+ CD4+ IL‐17+ T cells and the duration of disease before rituximab treatment were negatively associated with treatment responses. This ML model could be used to predict rituximab responses in paediatric ITP, which is expected to optimize treatment strategies and improve patient outcomes.
- Open Access
- 11 February 2025
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 9 (2)
Stepwise response-guided treatment protocol superior to thrombopoietin receptor agonist-based second-line therapy for severe persistent/chronic immune thrombocytopenia: a multicenter prospective study from China
- 11 February 2025
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 9 (2)
Open AccessStepwise response-guided treatment protocol superior to thrombopoietin receptor agonist-based second-line therapy for severe persistent/chronic immune thrombocytopenia: a multicenter prospective study from China